Immunohistochemical and clinical characteristics of the 12 MYC-negative B-cell lymphomas and SU-DHL-5 and HT cell lines (cohort 2)
| . | . | . | . | . | Immunohistochemistry . | . | . | Pathology panel . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | Age, gender . | Morphologic diagnosis . | Localization . | MYC . | CD20 . | CD10 . | CD5 . | BCL2 . | BCL6 . | MUM1 . | Ki67 . | EBER . | Treatment protocol . | Outcome, follow-up . | |
| Case 1 | 7, male | Aggressive B-NHL, BL | LN(c) | + | + | + | – | – | + | – | 90% | – | B-NHL BFM 04, treatment modified due to AT | In remission, alive, 62 mo | WK, IO, MMML panel |
| Case 2 | 7, male | BL | LN (colon) | – | + | + | – | – | + | na | 95% | – | NHL-BFM-95 | In remission, alive, 146 mo | WK, IO |
| Case 3 | 16, female | High-grade B-NHL, atypical BL | LN | – | + | + | na | + | + | + | 95% | – | NHL-BFM-95 | In remission, alive, 43 mo | WK, IO |
| Case 4 | 18, male | BL | LN(c) | + | + | – | – | + | na | >95% | – | GMALL 2008 | In complete remission, alive, 48 mo | WK, GR | |
| Case 5 | 22, male | BL | LN (ing) | + | + | – | – | – | na | >95% | – | GMALL 2002 | In complete remission, alive, 36 mo | WK, GR | |
| Case 6 | 25, male | BL | LN (ab) | + | + | – | – | + | na | >95% | – | CODOX-m 2003 | Dead (progression), 12 mo | WK, GR | |
| Case 7 | 37, female | BL | LN(c),T | + | + | – | – | + | na | >95% | – | GMALL 2002 | In complete remission, alive, 72 mo | WK, GR | |
| Case 8 | 11, male | Mature B-cell lymphoma/lymphoblastic B-lymphoma | LN(c) | + | + | – | – | + | na | >95% | na | EORTC 58951 | Alive, 3 mo | WK, EJ | |
| Case 9 | 12, male | BL | leg | + | + | + | – | – | + | – | >95% | – | B-NHL BFM 04 | Alive, 8 mo | WK, IO |
| Case 10 | 6, female | FL | LN (c) | + | + | na | – | + | – | >95% | – | Ritux + B-NHL BFM 04 | Alive, 24 mo | WK, IO | |
| Case 11 | 9, male | Atypical BL | LN(ing) | + | + | – | – | + | – | >95% | – | COG-ANHL01P1 | In complete remission, alive, 10 mo | WK, EJ | |
| Case 12 | 76, male | BL | LN (c) | – | + | + | na | w+ | na | na | >95% | na | Alive, na | WK, IO | |
| SU-DHL-5 | 17, female | B-NHL (DLBCL) | + | + | + | – | |||||||||
| HT | 70, male | B-NHL (DLBCL) | + | + | + | – | |||||||||
| . | . | . | . | . | Immunohistochemistry . | . | . | Pathology panel . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | Age, gender . | Morphologic diagnosis . | Localization . | MYC . | CD20 . | CD10 . | CD5 . | BCL2 . | BCL6 . | MUM1 . | Ki67 . | EBER . | Treatment protocol . | Outcome, follow-up . | |
| Case 1 | 7, male | Aggressive B-NHL, BL | LN(c) | + | + | + | – | – | + | – | 90% | – | B-NHL BFM 04, treatment modified due to AT | In remission, alive, 62 mo | WK, IO, MMML panel |
| Case 2 | 7, male | BL | LN (colon) | – | + | + | – | – | + | na | 95% | – | NHL-BFM-95 | In remission, alive, 146 mo | WK, IO |
| Case 3 | 16, female | High-grade B-NHL, atypical BL | LN | – | + | + | na | + | + | + | 95% | – | NHL-BFM-95 | In remission, alive, 43 mo | WK, IO |
| Case 4 | 18, male | BL | LN(c) | + | + | – | – | + | na | >95% | – | GMALL 2008 | In complete remission, alive, 48 mo | WK, GR | |
| Case 5 | 22, male | BL | LN (ing) | + | + | – | – | – | na | >95% | – | GMALL 2002 | In complete remission, alive, 36 mo | WK, GR | |
| Case 6 | 25, male | BL | LN (ab) | + | + | – | – | + | na | >95% | – | CODOX-m 2003 | Dead (progression), 12 mo | WK, GR | |
| Case 7 | 37, female | BL | LN(c),T | + | + | – | – | + | na | >95% | – | GMALL 2002 | In complete remission, alive, 72 mo | WK, GR | |
| Case 8 | 11, male | Mature B-cell lymphoma/lymphoblastic B-lymphoma | LN(c) | + | + | – | – | + | na | >95% | na | EORTC 58951 | Alive, 3 mo | WK, EJ | |
| Case 9 | 12, male | BL | leg | + | + | + | – | – | + | – | >95% | – | B-NHL BFM 04 | Alive, 8 mo | WK, IO |
| Case 10 | 6, female | FL | LN (c) | + | + | na | – | + | – | >95% | – | Ritux + B-NHL BFM 04 | Alive, 24 mo | WK, IO | |
| Case 11 | 9, male | Atypical BL | LN(ing) | + | + | – | – | + | – | >95% | – | COG-ANHL01P1 | In complete remission, alive, 10 mo | WK, EJ | |
| Case 12 | 76, male | BL | LN (c) | – | + | + | na | w+ | na | na | >95% | na | Alive, na | WK, IO | |
| SU-DHL-5 | 17, female | B-NHL (DLBCL) | + | + | + | – | |||||||||
| HT | 70, male | B-NHL (DLBCL) | + | + | + | – | |||||||||
−, negative; +, positive; ab, abdomen; c, cervical; EBER, Epstein-Barr–encoded RNA test; FL, follicular lymphoma; ing, inguinal; LN, lymph node; na, not available; NHL, non-Hodgkin lymphoma; T, tonsil; w, weak.
Cases 4, 5, 6, and 7 correspond to cases 1, 2, 3, and 4 from Pienkowska-Grela et al.8 Case 10 displayed a simultaneously follicular and diffuse grown pattern. Although its cytology showed features of BL, it was classified as FL grade 3 (minor component) with simultaneous DLBCL (major compartment), and it was included in a previous series of pediatric lymphomas already published; corresponds to case 23 from Oschlies et al13 and pFL8 from Martin-Guerrero et al.14 Information about SU-DHL-5 and HT cell lines was obtained from DSMZ (www.DSMZ.de). Lymphoma samples were scored positive if >25% of the tumor cells stained positive except for MYC, where the cutoff was established in 40%.